Press release

Lund 14 August 2013

**Broad launch for ColdZyme® Mouth Spray, soon on Apoteket AB’s shelves**

**The biotech company Enzymatica has signed an agreement with Apoteket AB, Sweden’s largest pharmacy chain. From early September, Enzymatica’s cold treatment product, ColdZyme® Mouth Spray, will be on sale at Apoteket AB.**

As of early September, Enzymatica’s registered medical device product against the common cold, ColdZyme® Mouth Spray, will form part of the regular range stocked by Apoteket AB and will be available from outlets throughout Sweden. The launch coincides with the beginning of the usual cold season, i.e. the end of the summer holidays and the start of the school year.

* We are very excited that ColdZyme® Mouth Spray has generated such a fantastic amount of interest. Over the past year, we have successfully introduced ColdZyme® Mouth Spray on the pharmacy market. This agreement is obviously a major leap forward for us commercially, since Apoteket AB is the largest pharmacy chain in Sweden, and has been part of our launch plan”, says Michael Edelborg Christensen, CEO of Enzymatica.

Enzymatica has already signed contracts with the pharmacy chains Apotek Hjärtat and Kronans Droghandel. The agreement with Apoteket AB means that ColdZyme® Mouth Spray will be available from the majority of Sweden’s 1,280 pharmacies.

ColdZyme® Mouth Spray was registered as a class 1 medical product in August 2012. The product is intended for use as a cold preventative, but if the spray is used during the early stages of a cold, it can also shorten the duration of the illness. One of the components of the mouth spray is an enzyme from deep sea cod which has excellent proven therapeutic properties. In Sweden, ColdZyme has been on sale at Kronans Droghandel and Apotek Hjärtat since the first quarter of 2013. Before then, it was available from specialist health product outlets.

**For more information, please contact:**

Michael Edelborg Christensen, CEO, Enzymatica AB (publ), +46 (0)768-14 41 66,

[michael.christensen@enzymatica.se](mailto:michael.christensen@enzymatica.se)

**About Enzymatica AB (publ)**

Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and registration of medical device products based on patented enzyme technology. Enzymatica utilizes a cold-adapted trypsin derived from deep-sea cod. This marine enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. Enzymatica has two registered medical device products, PeriZyme chewing gum CE, against oral cavity diseases and ColdZyme Mouth Spray CE against the common cold, the latter recently launched in pharmacies throughout the country.

**About Enzymatica online**

[Enzymatica’s press room »](http://www.mynewsdesk.com/se/pressroom/enzymatica-ab)

[Enzymatica’s website »](http://www.enzymatica.se/index.php?id=1)

[Enzymatica on LinkedIn »](http://www.linkedin.com/company/1586902?trk=tyah)

[Enzymatica on Twitter »](https://twitter.com/Enzymatica_AB)

[For Investors »](http://www.aktietorget.se/QuotesInstrument.aspx?Language=1&InstrumentID=SE0003943620)

[For Investors »](http://www.introduce.se/foretag/enzymatica)

[ColdZyme website »](http://www.coldzyme.se/)

[ColdZyme on Facebook »](http://www.facebook.com/pages/ColdZyme/162799103808769)